Zai Lab Announces Participation in March Investor Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024:

Leerink Partners Global Biopharma Conference 2024
Presentation: Monday, March 11, 2024, 4:00 p.m. ET
Location: Fontainebleau, Miami Beach
Room: Glimmer 3

A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and an archived replay will be available for up to 90 days following the completion of the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306695050/en/

For more information:

Investor Relations:
Christine Chiou / Lina Zhang
+1 (917) 886-6929 / +86 136 8257 6943
[email protected] / [email protected]

Media:
Shaun Maccoun / Xiaoyu Chen
+1 (415) 317-7255 / +86 185 0015 5011
[email protected] / [email protected]

Source: Zai Lab Limited

You May Also Be Interested In

• Barclays US LLC Annual Stress Test Results
• WISeKey and SEALSQ Establish Quantisimo Corp. as a Special Purpose Vehicle, and Execute Letter of Intent with GigCapital8 Corp.
• DLE Limited Announces Patent Filing for Ambient-Temperature Diamond Process and Offers Staged Disclosure Framework